How did Denavi Pharmaceuticals' revenue and expenses shift in Q4 2024?
4/14/2025 11:37am
Denavi Pharmaceuticals' revenue and expenses in Q4 2024 showed a significant cost of goods sold, with a reported $99.79 million, indicating a substantial shift in the company's financial focus during the period.
|code|Ticker|Name|Date|Cost of Goods Sold|R&D Expenses|Total Revenue|Advertising and Marketing Expenses|market_code|
|---|---|---|---|---|---|---|---|---|
|DNLI|DNLI.O|Denali|2024 Q1||1.07016E8|||185|
|DNLI|DNLI.O|Denali|2024 Q2||9.1399E7|0||185|
|DNLI|DNLI.O|Denali|2024 Q3||9.8238E7|||185|
|DNLI|DNLI.O|Denali|2024 Q4||9.9787E7|||185|